Sign in
MURA Stock Price, Chart, Stats & News
Mural Oncology plc
Save
Mural Oncology plc (MURA) does not currently pay a dividend.
35.38M
Market cap
–
Current P/E
–
Forward P/E
MURA chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -181.12% |
ROE | -131.47% |
D/E | 0.06x |
Interest coverage ratio | – |
MURA valuation
P/E | – |
P/S | – |
P/B | 0.64x |
P/CF | -0.30x |
P/FCF | -0.30x |
P/OCF | -0.30x |
PEG | -0.02x |
EV multiple | -0.77x |
About
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12.
Similar securities
Based on sector and market capitalization
Report issue